Healios (UK-based, healios.org.uk) is a digital healthcare company founded in 2013 that provides online mental health, autism, and ADHD services for children, young people, adults, and their families.[1][3][4] It builds the Panacea platform, a proprietary tool for remote assessments, video therapy sessions, appointment management, interactive tools, and family involvement, primarily serving the UK's healthcare sector through NHS partnerships and direct users.[1][3][4] The platform addresses critical gaps in accessible mental health support by enabling remote care, blending clinical expertise with technology to sustain healthier habits beyond sessions, with $28.59M raised (latest Series B in 2022) and reported revenue around $20.6M.[1][3]
This solves long waiting times and limited access to specialized care for neurodevelopmental conditions and mental illnesses, targeting ages 5+ with family-inclusive interventions.[1][4] Growth includes partnerships with the NHS, platform innovations like virtual supporter sessions, and expansion amid rising demand for digital mental health post-pandemic, though recent Mosaic Score declined -59 points.[1][3]
Healios emerged in 2013 in London, UK, after founders identified gaps in mental health support systems for children and young people, particularly the lack of accessible treatment and family involvement.[1][3] The company was driven by a mission to transform mental healthcare through technology, emphasizing support networks and remote delivery.[1] Early traction came from developing the Panacea platform and securing NHS partnerships, enabling scalable online services for autism, ADHD, and mental health.[1][4] Pivotal moments include raising $15.78M in Series B funding around 2022 and repositioning services amid evolving NHS needs, as highlighted in 2025 news on embracing mental health service changes.[1]
(Note: A separate Japanese biotech firm, Healios K.K., focuses on iPS cell therapies but is distinct from this UK digital health player.[2][5])
Healios rides the digital mental health wave, accelerated by post-pandemic demand for remote care and NHS pressures on child/young people services.[1] Timing aligns with UK policy shifts toward telehealth for neurodevelopmental conditions like autism/ADHD, where waiting lists exceed years, making scalable platforms essential.[1][4] Market forces favoring it include rising mental health awareness, government digital health investments, and family-involved care trends, positioning Healios to influence ecosystem-wide adoption of hybrid clinician-tech models.[1][3] It shapes the landscape by pioneering beyond-clinical interventions, inspiring competitors and informing NHS service evolution.[1]
Healios is poised to expand Panacea amid surging UK demand for child mental health tech, potentially deepening NHS integrations and international outreach.[1][4] Trends like AI-enhanced therapy tools and preventive family interventions will shape its path, boosting efficiency amid clinician shortages.[1][3] Its influence may grow as a benchmark for accessible digital care, evolving from startup to essential healthcare infrastructure—transforming gaps in support into "exceptional healthcare anytime, anywhere," as its mission promises.[3][4]
Healios has raised $29.0M in total across 3 funding rounds.
Healios's investors include Albion VC, Autism Impact Fund, Connect Ventures, WGI Group, James Meekings, Noah Goodhart.
Healios has raised $29.0M across 3 funding rounds. Most recently, it raised $16.0M Series B in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $16.0M Series B | Albion VC, Autism Impact Fund, Connect Ventures, WGI Group, James Meekings, Noah Goodhart | |
| May 1, 2021 | $10.0M Series A | Albion VC, Autism Impact Fund, Connect Ventures, WGI Group, James Meekings, Noah Goodhart | |
| Jun 1, 2018 | $3.0M Venture Round | Albion VC, Autism Impact Fund |
